サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795241

ヒト絨毛性ゴナドトロピン（hCG）の世界市場

Human Chorionic Gonadotropin (hCG)

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ヒト絨毛性ゴナドトロピン（hCG）の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒト絨毛性ゴナドトロピン（hCG）の世界市場は2030年までに9億8,520万米ドルに達する見込み

2024年に7億9,880万米ドルと推定されるヒト絨毛性ゴナドトロピン（hCG）の世界市場は、2030年には9億8,520万米ドルに達し、分析期間2024-2030年のCAGRは3.6%で成長すると予測されます。本レポートで分析したセグメントの1つである天然源抽出技術は、CAGR 4.2%を記録し、分析期間終了時には6億8,810万米ドルに達すると予測されます。リコンビナント技術分野の成長率は、分析期間中CAGR 2.1%と推定されます。

米国市場は2億1,760万米ドルと推定、中国はCAGR6.7%で成長すると予測

米国のヒト絨毛性ゴナドトロピン（hCG）市場は、2024年に2億1,760万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 6.7%で推移し、2030年には1億9,850万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4％と2.8％と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界のヒト絨毛性ゴナドトロピン（hCG）市場- 主要動向と促進要因のまとめ

生殖医療におけるhCGの役割拡大は市場需要をどのように形成しているか？

一般にhCGと呼ばれるヒト絨毛性ゴナドトロピンは、生殖医療分野において重要なホルモンとして認識されつつあり、不妊治療や早期妊娠の維持に重要な役割を果たしています。従来、hCGは妊娠中に自然に分泌されることで知られていたが、現在では体外受精や排卵誘発プロトコルを含む生殖補助医療技術に広く用いられています。hCGには黄体形成ホルモンを模倣する作用があるため、不妊治療を受けている女性の排卵を誘発する貴重な薬剤となり、妊娠の成功確率を高めるのに役立ちます。男性では、hCGは特に性腺機能低下症や不妊症の場合に、精巣を刺激してテストステロンと精子を産生させるために使用されます。このように、男性と女性の両方の生殖療法に応用できることから、不妊治療クリニック、病院、内分泌センターの間で需要が拡大しています。さらに、生殖に関する健康意識の高まりと診断ツールの利用可能性の高まりが、不妊症の問題の早期発見を促し、hCGのような治療用ホルモンの必要性をさらに高めています。初めて親になるカップルの年齢が上昇していることに加え、不妊率に影響する生活習慣の要因も相まって、hCGが治療の要となる臨床支援を求めるカップルが増えています。不妊の温存と介入が世界市場でより正常化するにつれ、hCGは生殖機能の回復や強化を目的としたプロトコールに不可欠なものとなり、ヘルスケアにおけるホルモン治療薬の拡大において重要な原動力となっています。

なぜhCGは診断および非生殖用途で注目を集めているのか？

hCGは妊娠や不妊治療と関連することが最も一般的ですが、その診断および治療用途は生殖医療の枠をはるかに超えており、医学の様々な分野でその関連性が高まっている一因となっています。hCGの生殖以外の用途として最もよく知られているのは妊娠検査で、血液や尿中のこのホルモンの検出は、妊娠初期の高感度マーカーとして機能します。しかし、hCGは精巣腫瘍、卵巣腫瘍、絨毛腫瘍など、特定のがんでも異常な量が産生されるため、腫瘍学では重要なバイオマーカーとなっています。医師は診断目的だけでなく、治療反応のモニタリングや悪性腫瘍の再発の可能性を検出するためにもhCG値を信頼しています。このため、がんスクリーニング・パネルや長期的な患者モニタリング戦略にhCG検査が組み込まれるようになりました。診断以外の分野では、体重管理や代謝調節のためのhCGへの関心が高まっているが、このような分野でのhCGの使用にはまだ議論の余地があり、医療当局が普遍的に支持しているわけではないです。一部のクリニックでは、hCGはカロリー制限ダイエット中の食欲を抑制し、筋肉量を維持するのに役立つという理論に基づいて、減量レジメンの一環としてhCG注射を販売しています。このような応用は世間の注目を集めているが、その有効性と安全性を見極めるためには、継続的な科学的評価が不可欠です。とはいえ、hCGの医学分野にわたる多様な役割は、生殖ホルモンを超えるものとしてその重要性を強調しており、より広範なヘルスケアにおける診断、治療、調査関連の意味を持つ多面的な薬剤として位置づけられています。

技術の進歩は、hCG療法の開発と提供をどのように強化しているのか？

技術革新は、hCGの合成、投与、モニタリングの方法を強化する上で極めて重要な役割を果たしており、それによってhCGの臨床応用の成長を支えています。組換えDNA技術の進歩により、高純度で一貫性のある合成hCGの生産が可能になり、従来の尿由来の供給源に代わる信頼性の高い供給源となっています。これにより、安全性プロファイルが改善され、コンタミネーションのリスクが減少したため、遺伝子組換えhCGは多くの治療場面で好ましい選択肢となっています。長時間作用型hCG製剤の製剤化も進歩の一途をたどっている分野であり、不妊治療中の注射回数を減らし、患者のコンプライアンスを高めることができるからです。これと並行して、プレフィルドシリンジや皮下注射ペンなどのドラッグデリバリーシステムの改良により、特に在宅治療プロトコルを受ける患者にとって、hCG投与がより使いやすくなっています。診断の面では、アッセイ技術の向上により、hCGレベルがより迅速かつ正確に検出されるようになり、非常に低濃度であっても感度が向上しました。このような改良は、臨床診断とポイントオブケア検査の両方に利益をもたらし、タイムリーな介入をサポートします。ウェアラブル健康機器やデジタル追跡プラットフォームもまた、特に不妊治療を受けている個人のために、個別化された健康管理ツールにhCGモニタリングを統合し始めています。診断プラットフォームへの人工知能と機械学習の統合は、臨床現場でのhCG値の解釈方法をさらに洗練させ、転帰の予測や治療計画の最適化に役立っています。これらの進歩はすべて、精密さと利便性が標準となりつつあるヘルスケアの、より広範なデジタルおよびバイオテクノロジーによる変革を反映しており、hCGはこの進歩の明らかな受益者となっています。

ヒト絨毛性ゴナドトロピン（hCG）市場の世界的成長を促進する要因は何か？

ヒト絨毛性ゴナドトロピン市場の世界の成長は、臨床需要、人口動態の変化、一般市民の健康意識の高まりが混在することによって牽引されています。最も大きな原動力の一つは、不妊に関連する問題の発生率の上昇であり、子作りの遅れ、ライフスタイルのストレス、環境毒素、生殖機能に影響を与える基礎的な健康状態などの要因が影響しています。妊娠するために医療支援を求めるカップルが増えるにつれ、hCGを含む不妊治療への需要は地域間で拡大しています。生殖補助医療技術の世界の普及と新興経済諸国における不妊治療クリニックの設立は、hCGを用いた不妊治療の新たな機会を生み出しています。不妊治療に加えて、腫瘍学や出生前診断における診断マーカーとしてのhCGの役割は、病院、診断研究所、専門クリニックでの有用性を高めています。バイオテクノロジーへの投資の拡大とバイオシミラーの開発により、hCG製品はより入手しやすく、手頃な価格になっています。生殖に関する健康と病気の早期発見を支援する政府の取り組みが、市場の拡大をさらに後押ししています。教育キャンペーンや市販の妊娠検査キットの普及により、消費者レベルでのhCG製品への関心が高まっています。さらに、製薬会社と研究機関とのコラボレーションが、hCG療法の新たな用途や送達方法の探求を後押ししています。これらの要素はすべて、ヒト絨毛性ゴナドトロピンが医学の様々な分野でその重要性を証明し続け、世界のヘルスケアの革新と提供の重要な要素となっている、ダイナミックで成長する市場環境の一因となっています。

セグメント

技術（天然源抽出技術、遺伝子組換え技術）

調査対象企業の例

  • Abbott Laboratories
  • Bayer AG
  • Bharat Serums and Vaccines Ltd
  • Biomed Pvt. Ltd.
  • Bristol Myers Squibb
  • Cardinal Health
  • Cipla Ltd.
  • EMD Serono（Merck KGaA）
  • Ferring Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • IBSA Institut Biochimique SA
  • Lupin Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Randox Laboratories Ltd.
  • Sanzyme Biologics
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37129

Global Human Chorionic Gonadotropin (hCG) Market to Reach US$985.2 Million by 2030

The global market for Human Chorionic Gonadotropin (hCG) estimated at US$798.8 Million in the year 2024, is expected to reach US$985.2 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Natural Source Extraction Technology, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$688.1 Million by the end of the analysis period. Growth in the Recombinant Technology segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$217.6 Million While China is Forecast to Grow at 6.7% CAGR

The Human Chorionic Gonadotropin (hCG) market in the U.S. is estimated at US$217.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$198.5 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Human Chorionic Gonadotropin (hCG) Market - Key Trends & Drivers Summarized

How Is the Expanding Role of hCG in Reproductive Health Shaping Market Demand?

Human Chorionic Gonadotropin, commonly referred to as hCG, is increasingly being recognized as a critical hormone in the field of reproductive medicine, where it plays a vital role in supporting fertility treatments and early pregnancy maintenance. Traditionally known for its natural production during pregnancy, hCG is now widely used in assisted reproductive technologies, including in-vitro fertilization and ovulation induction protocols. Its ability to mimic luteinizing hormone makes it a valuable agent for triggering ovulation in women undergoing fertility treatments, helping improve the chances of successful conception. In men, hCG is used to stimulate the testes to produce testosterone and sperm, particularly in cases of hypogonadism or infertility. This dual application across both male and female reproductive therapies is expanding its demand among fertility clinics, hospitals, and endocrinology centers. Additionally, the increasing awareness around reproductive health and the growing availability of diagnostic tools have encouraged early detection of fertility issues, further boosting the need for therapeutic hormones like hCG. The rising age of first-time parents, coupled with lifestyle factors affecting fertility rates, is prompting more couples to seek clinical support, where hCG serves as a cornerstone of treatment. As fertility preservation and intervention become more normalized across global markets, hCG continues to be integral in protocols that aim to restore or enhance reproductive function, making it a critical driver in the expansion of hormonal therapeutics within healthcare.

Why Is hCG Gaining Attention in Diagnostic and Non-Reproductive Applications?

While hCG is most commonly associated with pregnancy and fertility treatments, its diagnostic and therapeutic uses extend far beyond reproductive health, contributing to its growing relevance across multiple areas of medicine. One of the most well-known non-reproductive uses of hCG is in pregnancy testing, where the detection of this hormone in blood or urine serves as a highly sensitive marker for early gestation. However, hCG is also produced in abnormal quantities in certain cancers, including testicular, ovarian, and trophoblastic tumors, making it an important biomarker in oncology. Physicians rely on hCG levels not only for diagnostic purposes but also for monitoring treatment response and detecting potential recurrence of malignancies. This has led to the inclusion of hCG tests in cancer screening panels and long-term patient monitoring strategies. Beyond diagnostics, there has been growing interest in hCG for weight management and metabolic regulation, although its use in such areas remains controversial and is not universally endorsed by medical authorities. Some clinics market hCG injections as part of weight-loss regimens, based on the theory that it can help curb appetite and preserve muscle mass during calorie-restricted diets. While these applications have gained public attention, ongoing scientific evaluation is essential to determine their efficacy and safety. Nevertheless, the diverse roles of hCG across medical disciplines underline its significance as more than a reproductive hormone, positioning it as a multifaceted agent with diagnostic, therapeutic, and research-related implications in the broader healthcare landscape.

How Are Technological Advancements Enhancing the Development and Delivery of hCG Therapies?

Technological innovation is playing a pivotal role in enhancing how hCG is synthesized, administered, and monitored, thereby supporting the growth of its clinical applications. Advances in recombinant DNA technology have enabled the production of synthetic hCG with high purity and consistency, offering a reliable alternative to traditional urine-derived sources. This has improved safety profiles and reduced the risk of contamination, making recombinant hCG a preferred choice in many therapeutic contexts. The formulation of long-acting hCG preparations is another area of progress, as it allows for fewer injections and greater patient compliance during fertility treatments. In parallel, improvements in drug delivery systems, such as prefilled syringes and subcutaneous injection pens, have made hCG administration more user-friendly, particularly for patients undergoing home-based treatment protocols. On the diagnostic front, enhanced assay technologies have led to faster, more accurate detection of hCG levels, with greater sensitivity even at very low concentrations. These improvements benefit both clinical diagnostics and point-of-care testing, supporting timely interventions. Wearable health devices and digital tracking platforms are also beginning to integrate hCG monitoring in personalized health management tools, particularly for individuals undergoing fertility treatments. The integration of artificial intelligence and machine learning into diagnostic platforms is further refining how hCG levels are interpreted in clinical settings, helping predict outcomes and optimize treatment plans. All these advancements reflect the broader digital and biotechnological transformation of healthcare, where precision and convenience are becoming the norm, and hCG stands as a clear beneficiary of this progress.

What Factors Are Driving the Global Growth of the Human Chorionic Gonadotropin (hCG) Market?

The global growth of the human chorionic gonadotropin market is driven by a mix of clinical demand, demographic changes, and increased health awareness among the public. One of the foremost drivers is the rising incidence of fertility-related issues, influenced by factors such as delayed parenthood, lifestyle stress, environmental toxins, and underlying health conditions that impact reproductive function. As more couples seek medical help to conceive, the demand for fertility treatments that involve hCG is expanding across regions. The global spread of assisted reproductive technologies and the establishment of fertility clinics in developing economies are creating new opportunities for hCG-based interventions. In addition to fertility, the role of hCG as a diagnostic marker in oncology and prenatal care is increasing its utility in hospitals, diagnostic laboratories, and specialty clinics. Growing investments in biotechnology and the development of biosimilars are also making hCG products more accessible and affordable. Government initiatives supporting reproductive health and early disease detection are further propelling market expansion. Educational campaigns and wider availability of over-the-counter pregnancy test kits are increasing public interaction with hCG products at the consumer level. Furthermore, collaborations between pharmaceutical companies and research institutions are fueling the exploration of new applications and delivery methods for hCG therapies. All these elements contribute to a dynamic and growing market landscape, where human chorionic gonadotropin continues to prove its importance across various branches of medicine, making it a critical component of global healthcare innovation and delivery.

SCOPE OF STUDY:

The report analyzes the Human Chorionic Gonadotropin (hCG) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Natural Source Extraction Technology, Recombinant Technology)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Bayer AG
  • Bharat Serums and Vaccines Ltd
  • Biomed Pvt. Ltd.
  • Bristol Myers Squibb
  • Cardinal Health
  • Cipla Ltd.
  • EMD Serono (Merck KGaA)
  • Ferring Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • IBSA Institut Biochimique SA
  • Lupin Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Randox Laboratories Ltd.
  • Sanzyme Biologics
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Human Chorionic Gonadotropin (hCG) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Fertility Challenges Throw the Spotlight on hCG as a Core Hormonal Therapy in Assisted Reproduction
    • Increased IVF Procedure Volumes Propel Growth in Demand for hCG as a Trigger Injection
    • Here's the Story: Delayed Parenthood and Lifestyle Shifts Expand the Addressable Market for hCG Treatments
    • Advancements in Reproductive Health Diagnostics Drive Adoption of hCG-Based Monitoring and Intervention
    • Growing Medical Tourism for Fertility Treatments Spurs Global Demand for hCG Formulations
    • Expansion of Off-Label Use in Weight Loss and Muscle Building Generates Controversy and Regulatory Scrutiny
    • Increased Awareness of Male Hypogonadism and Hormonal Deficiencies Drives Use of hCG in Male Fertility Therapies
    • Here's How Pharmaceutical Innovation Supports the Development of Recombinant and Long-Acting hCG Products
    • Rising Demand for Home-Based and Self-Injectable Fertility Treatments Sustains Growth in Prefilled hCG Syringes
    • Availability of Biosimilars and Generic hCG Products Generates Price Competition and Expands Access
    • Technological Advancements in Drug Delivery Systems Propel Growth in Patient-Centric hCG Formats
    • Ethical and Doping Concerns in Sports Pose Compliance Challenges for hCG Distribution and Labeling
    • Clinical Research in Oncology and Endocrine Disorders Opens New Indications and Opportunities for hCG
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Chorionic Gonadotropin (hCG) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Chorionic Gonadotropin (hCG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Natural Source Extraction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Natural Source Extraction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Natural Source Extraction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Recombinant Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • JAPAN
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • CHINA
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • EUROPE
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Human Chorionic Gonadotropin (hCG) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • FRANCE
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • GERMANY
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Human Chorionic Gonadotropin (hCG) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • INDIA
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Human Chorionic Gonadotropin (hCG) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Human Chorionic Gonadotropin (hCG) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030
  • AFRICA
    • Human Chorionic Gonadotropin (hCG) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Human Chorionic Gonadotropin (hCG) by Technology - Natural Source Extraction Technology and Recombinant Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Human Chorionic Gonadotropin (hCG) by Technology - Percentage Breakdown of Value Sales for Natural Source Extraction Technology and Recombinant Technology for the Years 2014, 2025 & 2030

IV. COMPETITION